A controversial decision has been made by the UK's National Screening Committee (NSC), and it's one that has sparked debate and raised important questions. The NSC has advised against routine prostate cancer screening, stating that it could do more harm than good. But here's the twist: they've proposed a targeted approach for men with specific genetic variants.
In their draft recommendation, the committee highlighted the limitations of the prostate-specific antigen (PSA) test as a standalone screening method. They emphasized that even for high-risk groups like Black men and those with a family history, routine PSA testing may not be beneficial.
The NSC has opened a public consultation and is seeking further research to explore potential screening strategies. This is a critical step, as prostate cancer remains the most common cancer without a national screening program in the UK, with over 55,000 diagnoses and 12,000 deaths annually.
And this is the part most people miss: the risks of overtreatment. Evidence reviews have shown high rates of false-positive and false-negative results, and the challenge of distinguishing low-risk cancers from aggressive tumors. Unnecessary treatment can lead to severe long-term side effects, including incontinence and erectile dysfunction.
The committee plans to collaborate with Prostate Cancer UK's TRANSFORM trial, which aims to develop an effective screening approach. Dr. Ian Walker from Cancer Research UK supports this evidence-based approach, stating that the current evidence doesn't support routine screening.
But here's where it gets controversial: the targeted screening proposed by the NSC is for men with BRCA1 or BRCA2 gene variants. Dr. Walker and Professor Kamila Hawthorne from the Royal College of GPs agree that this targeted approach is sensible, but they also highlight a potential issue - many men may not know if they carry these mutations.
Professor Ros Eeles, co-lead of the TRANSFORM trial, welcomes the NSC's support for BRCA-specific screening but raises concerns about the age limit. She recommends annual screening from age 40 to 69, including male relatives of BRCA carriers, to catch aggressive cancers early.
Ben Lamb, a consultant urological surgeon, echoes these concerns, emphasizing that most men are unaware of their BRCA status. He highlights the incomplete family history information in GP records, which could impact screening decisions.
And this is where the decision becomes even more complex. Lamb points out that the NSC's decision not to offer targeted screening to other high-risk groups, like Black men, is a double-edged sword. Black men face a significantly higher risk of prostate cancer diagnosis and death, yet they are underrepresented in screening research.
Laura Kerby, CEO of Prostate Cancer UK, expresses disappointment with the decision, stating that screening BRCA carriers is just a fraction of the potential benefit of a broader program. She believes that research and evidence can drive change and save lives.
So, the question remains: is this targeted approach the best way forward? Or should we be aiming for a more inclusive screening program? What are your thoughts on this controversial decision? Feel free to share your opinions and insights in the comments below!
